SELLAS Life Sciences (SLS) Stock Jumps 20% After Hours as Phase 3 Leukemia Readout Nears
Key Takeaways
- •The Phase 3 REGAL trial testing galinpepimut-S in acute myeloid leukemia patients in second complete remission reached its 80th event in October, activating the final analysis, with topline overall survival results anticipated in November.
- •SLS shares climbed 20% in after-hours trading on the announcement, despite finishing the regular session down 4.63%, and have more than doubled in value year to date.
- •SELLAS recorded a third-quarter net loss of $10.1 million, or $0.05 per share, on zero revenue, in line with analyst estimates, while cash and equivalents rose roughly $62.9 million during the year to $134.7 million as of September 30.
- •The company's second leukemia candidate, SLS009, also known as tambiciclib, has enrolled 40 of 80 planned patients in a Phase 2 trial for newly diagnosed AML, with preliminary data expected in the fourth quarter.
- •Earlier Phase 2 results for SLS009 in relapsed or refractory AML showed response rates of 54% in monocytic disease and 57% in TP53-mutated disease, and those findings will be presented at the American Society of Hematology meeting in December.

Shares of SELLAS Life Sciences Group, Inc. (SLS) jumped 20% in extended trading Thursday after the company indicated that topline results from its Phase 3 leukemia trial are drawing near. The after-hours rally contrasted with the regular session, where the stock closed down 4.63%. Even so, shares have more than doubled in value so far this year.
Phase 3 REGAL Trial Hits Final-Analysis Trigger
The move followed SELLAS's announcement that its Phase 3 REGAL trial recorded its 80th event in October, the threshold that triggers the study's final analysis. The trial tests galinpepimut-S, or GPS, in patients with acute myeloid leukemia (AML) who are in second complete remission. Overall survival serves as the study's primary endpoint. Second complete remission is one of the more difficult settings in AML, a disease that has already relapsed once in these patients, and extending survival there is a central aim of new therapies.
With the event threshold reached, the next steps are database lock, unblinding, and statistical analysis. That sequence is the standard closing process for a blinded, event-driven trial, in which the final analysis is triggered by reaching a prespecified number of events rather than by a set date. Topline results are expected in November, within the fourth quarter. Chief Executive Angelos Stergiou said the company continues to execute across both clinical programs as milestones approach, though he did not provide a more specific date for the readout.
The Quarter in Numbers
SELLAS posted a third-quarter net loss of $10.1 million, or $0.05 per share, compared with a loss of $6.8 million, or $0.06 per share, a year earlier. The per-share loss narrowed even as the total loss widened, reflecting growth in the weighted-average share count to roughly 202.4 million from 108.4 million.
The company reported no revenue for the quarter, matching the consensus estimate of $0.00, and the per-share loss also matched Wall Street's forecast. A zero-revenue quarter is typical for a clinical-stage biotech whose drug candidates remain in testing.
Research and development spending rose to $7.0 million from $4.2 million, with the company pointing to manufacturing, consulting, and trial costs tied to a potential GPS regulatory filing. General and administrative expenses reached $4.3 million, up from $2.9 million. Loss from operations totaled $11.3 million for the quarter and $31.2 million for the nine-month period.
The company held cash and equivalents of $134.7 million as of September 30, up from $71.8 million at the end of 2025. That represents an increase of roughly $62.9 million during the year, arriving alongside rising spending tied to the potential GPS regulatory filing.
A Second Leukemia Program in the Wings
Beyond the REGAL readout, SELLAS's second leukemia program, SLS009, also known as tambiciclib, is being studied in a Phase 2 trial for newly diagnosed AML. Forty of the 80 planned patients have been enrolled, with preliminary data expected in the fourth quarter.
The company also highlighted completed Phase 2 data in relapsed or refractory AML, which showed response rates of 54% in monocytic disease and 57% in TP53-mutated disease, with median overall survival of 5.8 months and 8.8 months, respectively. SELLAS said those results compare favorably with historical outcomes of about 2.5 months, while cautioning that historical comparisons do not prove superiority in a randomized trial.
The company will present those findings at the American Society of Hematology meeting in December. Preclinical pancreatic cancer work also supports further study of SLS009 alongside RAS-directed therapy. With the REGAL topline due in November and SLS009 preliminary data expected in the same quarter, nearly all of SELLAS's near-term clinical milestones now fall within a single quarter-end window.